Thomas Yau
A5089328049- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver physiology and pathology
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
- HER2/EGFR in Cancer Research
- Hepatitis C virus research
- Gastric Cancer Management and Outcomes
- Breast Cancer Treatment Studies
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
University of Hong Kong
2016-2025
Chinese University of Hong Kong
2013-2025
Queen Mary Hospital
2016-2025
Hôpital Pontchaillou
2023
Toranomon Hospital
2020
Agios Pharmaceuticals (United States)
2014
State Key Laboratory of Synthetic Chemistry
2014
Harvard University
2014
Massachusetts General Hospital
2014
HKU-Pasteur Research Pole
2013
Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated efficacy of pembrolizumab this population.This randomized, double-blind, III study was conducted at 119 medical centers 27 countries. Eligible HCC, sorafenib, were randomly assigned a two-to-one ratio to receive plus best supportive care (BSC) or placebo BSC. Primary end points overall survival (OS)...
<h3>Importance</h3> Most patients with hepatocellular carcinoma (HCC) are diagnosed advanced disease not eligible for potentially curative therapies; therefore, new treatment options needed. Combining nivolumab ipilimumab may improve clinical outcomes compared monotherapy. <h3>Objective</h3> To assess efficacy and safety of plus in HCC who were previously treated sorafenib. <h3>Design, Setting, Participants</h3> CheckMate 040 is a multicenter, open-label, multicohort, phase 1/2 study. In the...
BackgroundA single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial unresectable hepatocellular carcinoma.MethodsIn this global, open-label, 3 trial, the majority patients we enrolled with carcinoma no previous systemic treatment were randomly assigned...
NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, reversible dual TKI, (L+C) in patients with centrally confirmed HER2-positive, metastatic breast cancer (MBC) ≥ 2 previous HER2-directed MBC regimens.Patients, including those stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day)...
This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 as monotherapies in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring single, priming dose of (ClinicalTrials.gov identifier: NCT02519348).Patients HCC who had progressed on, were intolerant to, or refused sorafenib randomly assigned to receive T300 + D (tremelimumab 300 mg...
Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses, manageable safety, and increased survival in patients with advanced hepatocellular carcinoma (HCC). In our retrospective analysis, we studied the immunobiology potential associations between biomarkers outcomes nivolumab HCC.Fresh archival tumour samples from dose-escalation dose-expansion phases of CheckMate 040 trial were analysed by immunohistochemistry RNA sequencing assess several inflammatory gene...
4012 Background: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% and median overall survival (mOS) 16 months (mo). This the first report efficacy safety + IPI combination in SOR-treated aHCC. Methods: Pts were randomized to 3 arms: [A] 1 mg/kg Q3W (4 doses) or [B] doses), each followed by 240 mg Q2W, [C] Q2W Q6W. Treatment continued until intolerable toxicity...
4004 Background: Pembro received accelerated approval based on results of KEYNOTE-224, a phase 2 trial in pts with advanced HCC the second line setting. KEYNOTE-240 (NCT02702401) was randomized, placebo (Pbo) controlled, 3 study vs BSC previously treated HCC. Methods: Eligible had radiographic or pathologic diagnosis HCC, progression on/intolerance to sorafenib, Child-Pugh A disease and ECOG PS 0-1. Pts were randomized 2:1 receive 200 mg + Pbo IV every wk, stratified by geographic region,...
Abstract Outcomes for patients with advanced hepatocellular carcinoma (HCC) remain poor despite recent progress in drug development. Emerging data implicate FGF19 as a potential HCC driver, suggesting its receptor, FGFR4, novel therapeutic target. We evaluated fisogatinib (BLU-554), highly potent and selective oral FGFR4 inhibitor, phase I dose-escalation/dose-expansion study using expression measured by IHC biomarker pathway activation. For dose escalation, 25 received 140 to 900 mg once...
Background Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICIs) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. We aimed evaluate the use of ipilimumab and anti-PD-1 ICIs (nivolumab or pembrolizumab) combinations patients HCC progression on prior ICIs. Methods Patients documented tumor subsequently received nivolumab/pembrolizumab were analyzed. Objective...
Pembrolizumab, a PD-1 inhibitor, demonstrated anti-tumour activity and tolerability in patients treated with sorafenib advanced hepatocellular carcinoma KEYNOTE-224. Longer-term efficacy safety after ∼2.5 years of additional follow-up are reported.Adults confirmed who experienced progression or intolerance to treatment received pembrolizumab 200 mg every 3 weeks for ≤35 cycles until progression, unacceptable toxicity, withdrawal consent investigator decision. The primary end-point was...
This randomized, open-label trial compared the efficacy and safety of adjuvant
LBA4008 Background: First-line therapies based on programmed death ligand 1 (PD-L1) inhibitors are standard of care (SOC) in uHCC and demonstrate improved outcomes over SOR; however, prognosis remains poor there is an unmet need for alternative with long-term benefits. Second-line NIVO + IPI demonstrated clinically meaningful efficacy manageable safety SOR-treated patients (pts) HCC CheckMate 040, leading to its accelerated approval the United States. We report first results from preplanned...
Nivolumab plus ipilimumab demonstrated promising clinical activity and durable responses in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC) the CheckMate 040 study at 30.7-month median follow-up. Here, we present 5-year results from this cohort.